ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatologic practice"

  • Abstract Number: 1723 • 2013 ACR/ARHP Annual Meeting

    Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition

    Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA

    Background/Purpose:  Gout is caused by a lack of efficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. …
  • Abstract Number: 1185 • 2013 ACR/ARHP Annual Meeting

    More Than One-Third Of Patients Reach Serum Urate Target and Continue To Report Multiple Flares

    Dinesh Khanna1, Puja Khanna2, Chris Storgard3, Scott Baumgartner4 and Robert Morlock5, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 34939 Directors Place, Ardea Bioscience, San Diego, CA, 4Ardea Biosciences, San Diego, CA, 5Ardea Bioscience, San Diego, CA

    Background/Purpose: Gout is a common inflammatory arthritis, and its worldwide prevalence is increasing. EULAR and ACR guidelines recommend a target serum urate (sUA) ≤6 mg/dL.…
  • Abstract Number: 1186 • 2013 ACR/ARHP Annual Meeting

    Use Of High-Dose Allopurinol To Reach Serum Uric Acid Targets In Patients With Gout Across Multiple Countries

    Jasvinder A. Singh1, Chris Storgard2, Scott Baumgartner3 and Robert Morlock4, 1Department of Medicine, University of Alabama, Tuscaloosa, AL, 24939 Directors Place, Ardea Bioscience, San Diego, CA, 3Ardea Biosciences, San Diego, CA, 4Ardea Bioscience, San Diego, CA

    Background/Purpose: Allopurinol is the most commonly used urate-lowering therapy (ULT) in the world. Although allopurinol is FDA approved for up to 800 mg/d and EMEA…
  • Abstract Number: 1187 • 2013 ACR/ARHP Annual Meeting

    A Large-Scale, Multicenter, Prospective, Open-Label, 6-Month Study To Evaluate The Safety Of Allopurinol Monotherapy In Patients With Gout

    Michael A. Becker1, David Fitz-Patrick2, Chris Storgard3, Matt Cravets4 and Scott Baumgartner5, 1Medicine, University of Chicago, Chicago, IL, 2East-West Medical Research Institute, Honolulu, HI, 34939 Directors Place, Ardea Bioscience, San Diego, CA, 4Ardea Biosciences, Inc., San Diego, CA, 5Ardea Biosciences, San Diego, CA

    Background/Purpose: Documentation of the safety profile of allopurinol at doses ≥300 mg/day is important for its ongoing use as first-line monotherapy or in combination with…
  • Abstract Number: 1189 • 2013 ACR/ARHP Annual Meeting

    Allopurinol Dose Titration and Efficacy: A Large-Scale, 6-Month, Multicenter, Prospective Study

    Scott Baumgartner1, Hyon Choi2,3, Nicola Dalbeth4, David Fitz-Patrick5, Matt Cravets6 and Chris Storgard7, 1Ardea Biosciences, San Diego, CA, 2Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Auckland District Health Board, Auckland, New Zealand, 5East-West Medical Research Institute, Honolulu, HI, 6Ardea Biosciences, Inc., San Diego, CA, 74939 Directors Place, Ardea Bioscience, San Diego, CA

    Background/Purpose: Allopurinol is the first-line urate-lowering therapy (ULT) for most people with gout, but target serum uric acid (sUA) levels of 200-300 >300-400 >400-500 >500-600…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology